Artiva Biotherapeutics, Inc.
ARTV
$10.79
-$0.09-0.83%
NASDAQ
| 06/30/2026 | 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | |
|---|---|---|---|---|---|
| Net Income | -6.33% | -13.21% | 3.51% | -1.29% | -4.64% |
| Total Depreciation and Amortization | 3.90% | 0.00% | 0.60% | 3.28% | 2.07% |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | 25.47% | 7.40% | 1.88% | 22.50% | -21.75% |
| Change in Net Operating Assets | 336.56% | -87.60% | 943.99% | 111.47% | -129.32% |
| Cash from Operations | 2.84% | -42.27% | 23.31% | 16.46% | -15.84% |
| Capital Expenditure | -71.49% | 42.52% | 29.83% | 43.13% | -106.46% |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | 15.70% | -5.49% | -2.47% | -23.89% | 111.57% |
| Cash from Investing | 14.81% | -4.51% | -1.46% | -22.93% | 111.83% |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | 63.64% | 2.94% | -6.25% | 3.03% | 0.00% |
| Issuance of Common Stock | -- | -- | -- | -- | -2.90% |
| Repurchase of Common Stock | 100.00% | -141.38% | 63.45% | -510.26% | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -13,019.08% | -- | -100.00% | 273.88% | -200.00% |
| Cash from Financing | 253,018.75% | 7.44% | -227.03% | 48.61% | -130.13% |
| Foreign Exchange rate Adjustments | -- | -- | -- | -- | -- |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | 4,981.64% | -581.64% | 140.30% | -53.13% | 79.93% |